REG - N4 Pharma PLC - Notice of AGM & Posting Annual Report and Accounts

N4 PharmaAnnouncement

24/02/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220224:nRSX6200Ca&default-theme=true

RNS Number : 6200C  N4 Pharma PLC  24 February 2022

 

24 February 2022

N4 Pharma Plc

("N4 Pharma" or the "Company")

Notice of Annual General Meeting

and

Posting of Annual Report and Accounts

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments and vaccines, announces
that the Company's audited accounts for the year ended 31 December 2021,
together with the notice of Annual General Meeting ("AGM"), are now available
on the Company's website www.n4pharma.com (http://www.n4pharma.com/)  and
will be posted to shareholders today.

The AGM will be held at 11.00am on 24 March 2022 at Shakespeare Martineau LLP,
6th Floor 60 Gracechurch Street, London, EC3V 0HR.

 

Enquiries:

 

 N4 Pharma Plc                                       Via IFC Advisory

 Nigel Theobald, CEO

 Luke Cairns, Executive Director

 SP Angel Corporate Finance LLP                      Tel: +44 (0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Caroline Rowe (Corporate Finance)

 Vadim Alexandre/Rob Rees (Corporate Broking)

 Turner Pope Investments (TPI) Limited               Tel: +44 (0)20 3657 0050

 Joint Broker

 Andy Thacker

 IFC Advisory Limited                                Tel: +44 (0)20 3934 6630

 Financial PR

 Graham Herring

 Zach Cohen

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for cancer and vaccine treatments using its unique silica nanoparticle
delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel
antigens for cancer and vaccine treatments to use Nuvec® as the delivery
vehicle to get their antigen into cells to express the protein needed for the
required immunity. As these products progress through pre clinical and
clinical programs, N4 Pharma will seek to receive up front payments, milestone
payments and ultimately royalty payments once products reach the market.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSEUFMDEESEIE